Blood coagulation factor calculation platform and method for treating hemophilia

Abstract

The invention discloses a blood coagulation factor calculation platform and method for treating hemophilia. The platform comprises a bleeding information collection unit for inputting and collecting the bleeding information of a patient; a bleeding information evaluation unit for evaluating the inputted and acquired bleeding information of the patient in combination with an expert consensus database unit to decide whether the patient needs an operation; a blood coagulation factor calculation unit used for calculating the administration dosage and the treatment course according to different conditions of an operation or no operation after whether the operation is needed is determined; and the expert consensus database unit used for storing and managing illness state evaluation standards andblood coagulation factor supplement standards of patients. According to the invention, the individualized administration dosage can be calculated for different types, different parts and different degrees of bleeding, operations, non-operations and the like in combination with the body weight of the patient and the activity basic level of the blood coagulation factor, and the corresponding administration treatment course is recommended, so that the individualized treatment of hemophilia patients is achieved.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a blood coagulation factor calculation platform and method for treating hemophilia. Background technique [0002] Hemophilia is a recessive hereditary bleeding disorder in which X-chromosomal gene mutations result in the deficiency of related coagulation factors. ) and hemophilia B (deficiency of coagulation factor IX (FIX)). According to the epidemiological survey in my country, the rate of hemophilia patients is 2.73 / 100,000. The incidence of hemophilia in men is much higher than that in women, the incidence of hemophilia A is 80.0%-85.0%, and the incidence of hemophilia B is 15.0%-20.0%. FVIII is mainly synthesized in the liver, vascular endothelium and other parts. FIX is a coagulation factor dependent on vitamin K and is mainly synthesized in liver. According to the activity level of FVIII / FIX, hemophilia A and B can be divided into 3 categories: mild (>5%-40%; major ...

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to provide a blood coagulation factor calculation platform and method for treating hemophilia, so as to solve the problem that the supplementary amount of blood coagulation factors in the prior art is generally based on the doctor’s clinical experience, or the doctor consults the data and gives the treatment It is difficult to control the supplementary dosage of blood coagulation factors scientifically and precisely

[0009] In order to realize the above-mentioned coagulation factor calculation platform and method for the treatment of hemophilia, the supplementary amount of coagulation factors in the prior art is generally based on the doctor’s clinical experience, or the doctor consults with the data and gives a treatment plan. For the supplementation of coagulation factors It is difficult to control the dose scientifically and precisely, the present invention provides the following technical solutions:

Images